A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.
Also called NCT02616666
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 632 participants
- Registry
-
NCT02616666 -
2015-001873-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02616666. Randomized; no masking; primary purpose treatment. Start 2016-08-25 (actual); primary completion 2025-12-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
- Acronym
- DECIDE
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Standard of Care
- Lead sponsor
- University of Liverpool
- Collaborator
- AstraZeneca
- Collaborator
- Clinical Practice Research Datalink
Record details
- Record id
cardio:ct-nct02616666- Content hash
caca5c6ba3ed5e83b572a9e615e4f64f888d873e1bc710f97159b956219384f5